Replies to post #402698 on Innovation Pharmaceuticals Inc (IPIX)

[Snowy_Owl]

I agree that there's a lot of interest in anti-fungal drugs particularly if continued climate change will increase and possibly compound the issue.

While I believe that B showing promise is the legitimate driver I'm wondering if applying for a patent is regarded simply as a way of placing a marker on what could be a promising drug. Also, there has to be an awareness of B nearing the end of license and does that have anything to do with the surge in patents?

I would hate for B to be swooped up by someone after IPIX investors have spent so much time and money pushing it to the 49 yard line. It would suck to have to watch some pharma with money, resources, and FDA influence spike 'our' B in the end zone.

Leo did not demonstrate well in his management of the office lease. Over the past few years I do not feel Leo has been putting forth the effort to advance B as his compensation should warrant. I guess we wait and see if Leo has the capability and the motivation to pursue bringing B to some degree of fruition.

[frenchbroad]

I would think an effective new anti-fungal combination of Bril + Caspofungin would be of great interest to BP

Yes. In particular this one: "Caspofungin (brand name Cancidas) is a lipopeptide antifungal drug from Merck & Co., Inc."
https://en.wikipedia.org/wiki/Caspofungin#:~:text=Caspofungin%20(INN%3B%20brand%20name%20Cancidas,%26%20Co.%2C%20Inc..
Because of this: "Caspofungin is a drug used to treat several types of fungal infections. Resistance to caspofungin is a huge problem, especially in those that are immunocompromised."
https://www.futuremedicine.com/doi/10.2217/fmb-2023-0236